文献速递流行病学与生物统计真实世界研究与卫生经济

政府政策干预减少人类抗菌药物使用:系统综述与证据图谱

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map.
PubMed 文献 · PLoS Med · 2019-06-11

该系统综述检索7个数据库至2019年1月28日,纳入69项政府政策干预评估,覆盖WHO六个区域中的四个,识别出17种减少人类抗菌药物使用的政策选项,评估设计包括随机对照试验4项、中断时间序列25项等。作者认为这是首个为政策制定者提供政府政策干预合成证据的研究,并建议未来确保采用严谨设计评估政策并发表结果。

要点

  • 共纳入69项政府政策干预评估,覆盖WHO六个区域中的四个。
  • 识别出17种减少人类抗菌药物使用的政策选项,包括公众意识运动(17项)和抗菌药物指南(13项)。
  • 评估设计包括随机对照试验4项、非随机对照试验3项、对照前后设计7项、中断时间序列25项等。

核心结论

  • 作者认为这是首个为政策制定者提供针对抗菌药物耐药性的特定政府政策干预合成证据的研究。
  • 作者建议未来政府应确保采用严谨的研究设计评估抗菌药物耐药性政策干预,并发表研究结果。

研究设计与样本

  • 系统综述与证据图谱,检索7个数据库(MEDLINE、CINAHL、EMBASE、PAIS Index、Cochrane Central Register of Controlled Trials、Web of Science和PubMed)从建库至2019年1月28日。
  • 纳入标准为清晰描述旨在减少人类抗菌药物使用的政府政策干预并采用定量设计测量影响的研究,共纳入69项独特评估。
  • 纳入评估的设计包括随机对照试验4项、非随机对照试验3项、对照前后设计7项、中断时间序列设计25项、非对照前后设计18项、描述性设计10项和队列设计2项。
  • 方案注册号:PROSPERO CRD42017067514。

主要发现

  • 69项评估覆盖WHO六个区域中的四个。
  • 识别出17种可供政府减少人类抗菌药物使用的独特政策选项。
  • 许多研究评估了公众意识运动(17项)和抗菌药物指南(13项),其他政策选项包括专业监管、限制报销、按绩效付费和处方要求。

局限性

  • 研究局限性包括可能遗漏未发表的倡议。
  • 未针对抗菌药物使用进行评估的政策未被本综述纳入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidence map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. PROTOCOL REGISTRATION: PROSPERO CRD42017067514.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Rogers Van Katwyk S, Grimshaw JM, Nkangu M, et al. Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map. PLoS Med. 2019. PMID: 31185011. doi:10.1371/journal.pmed.1002819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。